GlassScriptPhysician profile
Rachel Weaver
NPI 1588084768
$2,266.18
in general payments reported to CMS, 2019-2025
19 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $186 · 2023: $869 · 2024: $524 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,867.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $362.40 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $311.26 | 2021-2022 | |
| Glaxosmithkline, LLC. | $241.17 | 2023 | Arexvy, Bexsero |
| Inspire Medical Systems, INC. | $133.53 | 2024 | Inspire |
| Kowa Pharmaceuticals America, INC. | $124.80 | 2025 | Zoryve |
| Kyowa Kirin, INC. | $121.86 | 2025 | |
| Gilead Sciences, INC. | $116.15 | 2025 | Epclusa |
| Axsome Therapeutics, INC. | $112.12 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.13 | 2023 | Jardiance |
| Abbvie INC. | $105.64 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $90.93 | 2024 | Rexulti |
| Amgen INC. | $77.60 | 2023 | Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.54 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $67.26 | 2023 | |
| Vapotherm INC | $66.17 | 2023 | Vapotherm |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $61.43 | 2024 | |
| Coloplast Corp | $56.33 | 2023 | Titan |
| Astrazeneca Pharmaceuticals LP | $21.86 | 2023 | Farxiga |
| Sun Pharmaceutical Industries INC. | $19.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.